Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-09-2011 | Editors Choice

Arida A, Fragiadaki K, Giavri E, Sfikakis PP (2010) Anti-TNF Agents for Behçet´s disease: analysis of published data on 369 patients. Semin Arthritis Rheum [PMID:21168186]

Authors: Nicole Stuebiger, Dicle Hazirolan, Uwe Pleyer

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 9/2011

Excerpt

…

BenEzra D, Cohen E (1986) Treatment and visual prognosis in Behçet´s disease. Br J Ophthalmol 70:589–592PubMedCrossRef

Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti-Pezzi P (2007) Infliximab treatment for ocular and extraocular manifestations of Behçet´s disease. Jpn J Ophthalmol 51:191–196PubMedCrossRef

Kötter I, Günaydin I, Zierhut M, Stübiger N (2004) The use of interferon alpha in Behçet´s disease: review of the literature. Semin Arthritis Rheum 33:320–335PubMedCrossRef

Deuter CM, Zierhut M, Möhle A, Vonthein R, Stübiger N, Kötter I (2010) Long term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet´s disease. Arthritis Rheum 62:2796–2805PubMedCrossRef

Geudry J, Wechsler B, Terrada C, Gendron G, Cassoux N, Fardeau C, Lehoang P, Piette JC, Bodaghi B (2008) Long-term efficacy and safety of low-dose interferon α2a therapy associated with Behçet´s disease. Am J Ophthalmol 146:837–844CrossRef

Kötter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Günaydin I, Grimbacher B, Blaschke S, Mayer-Riemann W, Peter HH, Stübiger N (2003) Human recombinant interferon-α2a for the treatment of Behçet´s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87:423–431PubMedCrossRef

Krause L, Altenburg A, Pleyer U, Köhler AK, Zouboulis CC, Foerster MH (2008) Long-term visual prognosis of patients with ocular Adamantiades–Behçet´s disease treated with interferon-α2a. J Rheumatol 35:896–903PubMed

Stübiger N, Kötter I, Deuter C, Zierhut M (2001) Behçet´s disease: uveitis therapy with interferon-α2a — prospective study in 33 patients. Klin Monatsbl Augenheilkd 218:768–773PubMedCrossRef

Hatemi G, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, Kötter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stübiger N, Yurdakul S, Yazici H: EULAR Expert Committee (2008) EULAR recommendations for the management of Behçet's disease. Ann Rheum Dis 67:1656–1662PubMedCrossRef

Title: Arida A, Fragiadaki K, Giavri E, Sfikakis PP (2010) Anti-TNF Agents for Behçet´s disease: analysis of published data on 369 patients. Semin Arthritis Rheum [PMID:21168186]
Authors: Nicole Stuebiger
Dicle Hazirolan
Uwe Pleyer
Publication date: 01-09-2011
Publisher: Springer-Verlag
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 9/2011
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-011-1717-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Arida A, Fragiadaki K, Giavri E, Sfikakis PP (2010) Anti-TNF Agents for Behçet´s disease: analysis of published data on 369 patients. Semin Arthritis Rheum [PMID:21168186]

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 9/2011

Learning effect of dark adaptation among normal subjects

c-Jun N-terminal kinase is involved in the regulation of proliferation and apoptosis by integrin-linked kinase in human retinoblastoma cells

Subretinal lymphomatous infiltration in primary intraocular lymphoma revealed by optical coherence tomography

Intravitreal bevacizumab versus photodynamic therapy for myopic choroidal neovascularization in a North-African population

Measurement of distance objective visual acuity with the computerized optokinetic nystagmus test in patients with ocular diseases

An ex vivo model of coxsackievirus infection using multilayered human conjunctival epithelial cells